Hematologic Oncology Update

Latest Episodes:

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting Oct 12, 2026

Show notes

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:

Introduction (0:00)
New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)
Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)
Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12)

CME information and select publications

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management Oct 08, 2026

Show notes

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:

Introduction (0:00)
Minimal Residual Disease Assays in Community-Based Practice (1:24)
New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)
Richter Transformation (30:43)
Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)

CME information and select publications

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies Oct 05, 2026

Show notes

Featuring an interview with Dr L Elizabeth Budde, including the following topics:

Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)
Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)
Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun study (17:30)
Case: A man in his mid 50s with relapsed/refractory (R/R) DLBCL receives mosunetuzumab and polatuzumab vedotin in the second-line setting (23:18)
Case: A woman in her early 70s with R/R DLBCL receives glofitamab monotherapy in the third-line setting (32:52)
Case: A man in his early 80s with R/R DLBCL experiences disease progression after lisocabtagene maraleucel therapy, which was bridged with epcoritamab and gemcitabine/oxaliplatin (37:35)

CME information and select publications

Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network Oct 01, 2026

Show notes

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

Introduction (0:00)
First-Line Treatment (1:33)
Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)

CME information and select publications

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network Sep 28, 2026

Show notes

Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

Introduction (0:00)
First-Line Therapy (2:48)
Relapsed/Refractory Disease (39:30)

CME information and select publications

Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress Sep 25, 2026

Show notes

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:

Introduction (0:00)
Trials in Progress (1:12)
Chronic Lymphocytic Leukemia (7:09)
Diffuse Large B-Cell Lymphoma (32:35)
Mantle Cell Lymphoma (58:25)
Follicular Lymphoma (1:14:49)

CME information and select publications

Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov Sep 23, 2026

Show notes

Featuring an interview with Dr Douglas W Sborov, including the following topics:

DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)

CME information and select publications

Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus Sep 12, 2026

Show notes

Featuring an interview with Prof Andreas Hochhaus, including the following topics:

Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)
Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)
Potential mechanisms of adverse events documented with TKIs (10:23)
Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)
Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)
Comparative efficacy of asciminib and other agents used to treat CML (40:01)
Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)
Practical care strategies for CML patients; future developments (52:32)

CME information and select publications

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4 Sep 07, 2026

Show notes

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)
Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)
Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)

CME information and select publications

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3 Sep 06, 2026

Show notes

Featuring perspectives from Prof John Seymour, including the following topics:

Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Hematologic Oncology Update

Related Podcasts

Links

Stay Connected